Contract facts
FederalNo full NAICS 325411 intel page yet. Browse NAICS intelligence
4569234695!VANCOMYCIN 1 GM VIALS is a federal award for Dla Troop Support held by Hikma Pharmaceuticals Usa Inc. Estimated value $237K ($237K obligated). Current period of performance ends Aug 26, 2025. Place of performance: BERKELEY HEIGHTS NJ.
Recompete timing
PublicCurrent PoP ended Aug 26, 2025 (360 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract SPE2D325F344A?
SPE2D325F344A (4569234695!vancomycin 1 GM VIALS) is a Dla Troop Support award with a potential value of $237K, currently held by Hikma Pharmaceuticals Usa Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded SPE2D325F344A?
Dla Troop Support awarded SPE2D325F344A to Hikma Pharmaceuticals Usa Inc (potential $237K).
Who is the incumbent on SPE2D325F344A?
Hikma Pharmaceuticals Usa Inc is the incumbent. The current period of performance ends Aug 26, 2025.
When does Hikma Pharmaceuticals Usa Inc’s SPE2D325F344A come up for recompete?
SCOUT tracks a period-of-performance end of Aug 26, 2025. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.